Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
ANL
SELLAdlai Nortye Ltd. · Healthcare · United States · $805M · Avg Vol: $3M/d
COMPANY DESCRIPTION
Adlai Nortye Ltd. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for cancer. The company's competitive edge lies in its proprietary drug candidates targeting immune checkpoints and other novel pathways in oncology, aiming to address unmet medical needs. It operates as a niche player within the highly specialized field of cancer therapeutics, leveraging its R&D capabilities.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 45.7M | 0 | 0 | 0 | 5.0M | -42.5% | 5.0M | 4.6M | -8.3% |
| EPS | -1.54 | -1.59 | -7.56 | -1.62 | -3.33 | — | -1.15 | — | — |
| Shares | 110.7M | 110.7M | 110.7M | 110.7M | 58.7M | -46.9% | 58.7M | — | — |
| Debt | 13.3M | 6.5M | 31.5M | 27.2M | 26.4M | 18.6% | 26.4M | — | — |
| Equity | -185.4M | -241.3M | 75.0M | 25.5M | -8.3M | -66.0% | — | — | — |
| Op CF | -3.0M | -43.2M | -56.7M | -51.8M | -33.5M | — | -33.5M | — | — |
| Inv CF | -54.9M | 28.4M | -11.0M | 28.1M | -15.6M | — | — | — | — |
| Fin CF | 97.2M | -6.8M | 116.2M | -6.6M | -3.8M | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ANL are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ANL | Adlai Nortye Ltd.(you) | $805M | 24 | SELL |
| SLDB | Solid Biosciences Inc. | $771M | 25 | SELL |
| AURA | Aura Biosciences, Inc. | $729M | 24 | SELL |
| DRUG.CN | Bright Minds Biosciences Inc. | $727M | 24 | SELL |
| REPL | Replimune Group, Inc. | $814M | 26 | SELL |
| JANX | Janux Therapeutics, Inc. | $935M | 24 | SELL |
| DSGN | Design Therapeutics, Inc. | $736M | 26 | SELL |
| STTK | Shattuck Labs, Inc. | $710M | 26 | SELL |
| ACRS | Aclaris Therapeutics, Inc. | $730M | 21 | SELL |
| AVTX | Avalo Therapeutics, Inc. | $976M | 25 | SELL |
Peer medians: ROE -25.5% · P/E 27.6x · Gross margin 50.5%